pharm edaily

[Kim Saemi, Edaily Reporter] SyntekaBio, Inc. is beginning to show tangible results from its proprietary artificial intelligence (AI) drug discovery platform, DeepMatcher. The company recently signed successive drug optimization contracts with Sungkyunkwan University School of Medicine and natural product-based new drug developer Enbios, signaling the full-fledged acceleration of AI-driven drug discovery achievements.

SyntekaBio and Enbios sign partnership agreement at the Daejeon ABS Center on Sept. 25. (Source: SyntekaBio, Inc.)

According to the company on the 26th, SyntekaBio signed a service contract on September 22 with Professor Dong-Ik Kim’s team at Sungkyunkwan University School of Medicine for “drug optimization using DeepMatcher.” Professor Kim’s team is carrying out the “anti-aging reversal project,” part of the Industrial Technology Alchemist Program overseen by the Korea Evaluation Institute of Industrial Technology under the Ministry of Trade, Industry and Energy.

The contract aims to enhance the efficacy of one candidate compound in the project by applying DeepMatcher and to identify new compounds. SyntekaBio plans to conduct research based on natural product-derived ingredients, including analyzing key residues in protein?compound binding, designing derivatives using DeepMatcher, and discovering novel compounds. The research is scheduled to continue through December 31.

Following that, on September 25 SyntekaBio signed a DeepMatcher service contract and a strategic partnership agreement with Enbios, a biotech specializing in natural product-based drug development.

The two companies will jointly optimize candidate compounds targeting cancer indications using DeepMatcher and generate new chemical entities. They also plan to secure joint intellectual property (IP) rights for newly discovered substances and pursue commercialization based on those rights.

A SyntekaBio official stated, “Unlike ordinary short-term service contracts, these agreements carry significance as strategic partnerships that could translate into long-term revenue. Based on DeepMatcher’s technological capabilities, we aim to deliver tangible and visible results in the drug development field.”